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Abstract
Background: We have devised a simple and efficient fluorescence-based method to track antigen
uptake and processing in human B lymphoblastoid cells (B-LCL). Fluorescein labelled subtilisin was
used to optimize antigen uptake conditions and identify processed peptides from human cell lines.
Results: Fluorescein labelled subtilisin conjugates had 0.06 to 2 moles of fluorescein per subtilisin
molecule. High performance liquid chromatography and mass spectrometry (NanoESI-LC/MS/MS)
analysis identified fluorescein conjugated to K141, K256, and the N terminus. Conjugates retained
antigenic specificity to subtilisin specific antibodies and could be processed by whole cell extracts
into low molecular weight fragments at pH 5.2. Maximal antigen uptake and processing occurred
when PMSF (phenylmethylsulfonyl fluoride) inhibited subtilisin conjugate was incubated with cells
at 100–200 µg/ml for 16 to 24 hr. Once optimal uptake conditions were established, processed
subtilisin peptides were isolated and identified from human cell lines.
Conclusion: Our studies show that FITC-conjugation provides an efficient tool to track the
uptake and processing of this protease antigen and to facilitate identification of processed antigenic
peptides from human cell lines.
Background
Antigen presentation by MHC class I and class II mole-
cules is a key aspect of an effective immune response
against infections, cancer, certain allergic responses and
autoimmune disease. Several good reviews cover capture
and processing of exogenous antigens [1,2]. The detection
and identification of antigen-derived peptides is impor-
tant to understand the mechanisms involved in the
immune response and to be able to modulate it. Though
some studies have employed synthetic peptides to detect
peptide epitopes, this approach is unable to identify nat-
urally processed and presented peptides. Some of the early
methods employed for identification of naturally proc-
essed endogenous epitopes were HPLC and Edman degra-
dation, which led to the identification of hen egg
lysozyme (HEL) 52–61 on the MHC of murine B lym-
phoma cells expressing HEL [3]. Hunt et al. showed the
power of joining immunological procedures and mass
spectrometry to identify self-peptides presented on cell
surfaces in picomole or less concentrations from mouse
and human cell lines [4-6]. Using mass spectrometry, Vig-
nali et al. identified 16 peptides from HEL, which con-
tained the minimal HEL 52–61 epitope as the single
immunodominant epitope in a nested set of peptides [4].
Using tandem mass spectrometry and functional analysis
with SEQUEST software, Dongre, et al. identified 128 self-
peptide sequences displayed by murine MHC class II mol-
ecules [7].
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In the case of exogenous antigens such as ovalbumin [8],
tetanus toxoid [9], Goodpasture antigen [10] and diabetes
autoantigen [11], many investigators have used a modi-
fied delivery system to identify class II MHC peptides.
Studies on exogenous class II peptides are limited as a
result of requiring large amounts of purified antigen with
over 109 cells, and the target peptides appearing in pico-
mole quantities or less [12], often present as a subset of
nested peptides thus diluting the mass spectrometric sig-
nal and rendering detection difficult.
Previous studies from our laboratory have identified class
II epitopes from the subtilisin antigen, using synthetic
subtilisin peptides with human dendritic cells and naive
CD4+ T cells derived from the same donor [13]. In order
to identify naturally processed epitopes, we have devel-
oped an efficient method of tracking protein in the cell
using fluorescein-conjugated antigen. Fluorescent pro-
teins have been used to track microvascular permeability
[14], to study intestinal epithelial cell uptake [15], to
study substrate processing [16,17] and to track proteins
on cells with flow cytometry [18,19]. With the availability
of the latest mass spectrometric methods, we investigated
the use of fluorescein to study antigen uptake and process-
ing. We describe here the use of FITC conjugated subtilisin
in antigen uptake experiments and methods to track the
processing of subtilisin both in vitro and in vivo in human
cell lines.
Results
Preparation and characterization of FITC-subtilisin
FITC-labelled subtilisin (FITC-subtilisin) was prepared by
derivatizing amino groups on the PMSF-inactivated sub-
tilisin, using 10-fold molar excess of FITC. FITC-subtilisin
was purified and assayed for relative fluorescent units
(RFU) per microgram protein. The RFU signal was linear
from 0.1 to 100 RFU/well and conjugates ranged from 0.6
to 22 RFU/µg protein, corresponding to 0.06 to 2.1 moles
of FITC per mole of protein. Conjugates with low ratios of
FITC to subtilisin were obtained by increasing the concen-
tration of enzyme in the reaction. Conjugates were TCA-
precipitable and showed 89–93% of the fluorescein signal
in the pellets. Generally 2 moles or less of FITC were cou-
pled per mole of subtilisin.
FITC-subtilisin showed 10% enzyme activity compared to
the unmodified subtilisin, as tested on the synthetic sub-
strate, sucAAPF-pNA [20], as a result of residual PMSF
bound to FITC-subtilisin (data not shown).
Identification of FITC-labelled sites on subtilisin using LC-
MS
LC-MS was employed to confirm FITC modification of
subtilisin. A deconvoluted LC-MS mass spectrometry pro-
file of the modified protein showed free subtilisin (27,476
Da) and FITC-subtilisin with one (27,865 Da) and two
moles of FITC (28, 255 Da) (Figure 1). To localize the
amino groups on subtilisin modified by FITC, TCA precip-
itated FITC-subtilisin was hydrolysed with trypsin, which
cleaves preferentially at lysine residues. Figure 2 shows
identification of subtilisin peptide 137–145 that con-
tained the FITC-modification at the lysine 141 residue.
Using fragmentation software analysis, the N-terminus
and sites K256 and K141 were also identified as FITC-
modification sites.
FITC-subtilisin is immunoreactive and degraded by human 
B-LCL extracts
To ensure that the overall structure of subtilisin was
unchanged, we bound FITC-subtilisin with anti-subtilisin
antibody and tracked immunoadsorption using the fluo-
rescein label. Relative fluorescent units showed over 40%
of the FITC-subtilisin bound to rabbit polyclonal anti-
subtilisin antibody (Table 1). We have routinely used this
antibody to track unmodified subtilisin in western blots
(data not shown). As a positive control, a mouse anti-FITC
monoclonal antibody was used to immunoprecipitate the
FITC-subtilisin. No significant binding was observed to
normal rabbit gamma globulin control.
To determine whether FITC-subtilisin would be processed
by cellular enzymes used in the antigen processing
machinery, FITC-subtilisin was incubated with whole cell
extracts from Preiss cells. To track processing, low molec-
ular weight fragments were separated with a centrifugal
filtration device and relative fluorescent units in the flow-
through were measured. Control samples contained
PMSF to retard autolysis of subtilisin and prevent process-
ing by the cellular enzymes. Cell extracts from Preiss cells
generated significant amounts of low molecular weight
peptides at pH 5.3, the pH of endocytic compartments
within the cell, compared to controls (See Table 2). At pH
7, however, autolysis of FITC-subtilisin was comparable
to the hydrolysis by the cell extracts. Similar results were
obtained with whole cell extracts from cell line 8.1.6.
These results showed that FITC-subtilisin was susceptible
to hydrolysis in vitro by mammalian cellular enzymes and
could be used to track and detect peptides generated from
antigen processing.
Establishing optimal conditions for antigen uptake and 
processing in human B-LCL
Once we established that FITC-subtilisin was comparable
in overall structure to unmodified subtilisin and capable
of being processed in vitro, we tracked uptake and process-
ing in vivo in cells. FITC-subtilisin was co-incubated with
Preiss cells for 24 hours, the cells were lysed in acid and
RFU were analyzed in the low molecular weight fractions
of the cell lysates (See Table 3).BMC Immunology 2004, 5:12 http://www.biomedcentral.com/1471-2172/5/12
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Using this relatively simple method, we tested several dif-
ferent conditions that could facilitate antigen uptake and
processing. We compared uptake of enzymatically active
FITC-subtilisin, TCA-precipitated FITC-subtilisin and
autolyzed FITC-subtilisin in 8.1.6 cells (Table 4). Enzy-
matically active subtilisin degraded the cells and was not
used in subsequent experiments. Significantly more TCA-
precipitated subtilisin was associated with the washed cell
pellet though only 0.06% RFU were recovered from the
low molecular weight fraction. Similarly, incorporation of
FITC-subtilisin in lysosomes and commercial carriers
resulted in increased RFUs in the cell pellet but did not
convert into significant increases in low molecular pep-
tides (See Table 5). Multimers of FITC-subtilisin prepared
by glutaraldehyde coupling or antibody FITC-subtilisin
conjugates also failed to show increased processing. The
early (2–12 hour) and late (36–48 hour) time points did
not show significant increase in uptake and processing;
neither did increasing antigen dose. Using greater num-
bers of cells as well as incubating antigen for 16 to 24
hours, however, did result in greater uptake and
processing.
Identification of processed FITC-subtilisin peptides in 
human B-LCL cells
Based on our results of optimal conditions for uptake and
processing, 4–6 × 109 cells were incubated with 0.2 mg/ml
FITC-subtilisin (0.6 mole FITC/mole subtilisin) for 24
hours. The cell pellets were either acid treated directly as
described above or processed for DR extraction; low
LC/MS Analysis of FITC-Subtilisin Figure 1
LC/MS Analysis of FITC-Subtilisin. The de-convoluted mass spectrum shows the un-labeled subtilisin (27,476 Da), subtili-
sin conjugated to one (27,865 Da) or two (28,255 Da) FITC molecules.
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molecular weight fractions were analyzed for RFUs and
then by mass spectrometry. For DR-extraction, the cells
were washed and lysed and loaded on a HLA-DR immu-
noaffinity column. The column flow-through had signifi-
cant RFU. This was fractionated and the low molecular
weight fraction was concentrated. HLA-DR molecules
purified by the immunoaffinity column were isolated and
DR-bound peptides were acid-eluted from these mole-
cules. Half as many RFUs were detected from the DR-
eluted peptides (See Table 5). Both samples were analyzed
by LC-MS spectroscopy. A subtilisin peptide was identi-
fied from the flow-through sample.
Subtilisin peptide 114–126 found in the flow-through
was confirmed by spiking a synthetic version of this pep-
tide in control cell extracts and comparison of the syn-
thetic peptide with the unknown peptide by retention
time, m/z charge, and fragmentation pattern. Overall,
three subtilisin regions were identified from cellular
extracts of cells incubated with antigen but not from con-
trol cell extracts not incubated with antigen, by ms/ms
fragmentation in multiple experiments (See Table 6).
Nested sets of peptides from these regions were consist-
ently observed in two or more experiments. However,
peptides were not detected in the DR-eluted fraction of
the extracts.
To test whether DR associated peptides could be detected
in other cell lines, KG-1 cells (dendritic-like cell line
derived from monocytes) were incubated with FITC-sub-
LC/MS/MS analysis of tryptic digested FITC-Subtilisin Figure 2
LC/MS/MS analysis of tryptic digested FITC-Subtilisin. Top panel: Full base peak MS spectrum and base peak search 
spectrum for FITC molecule at m/z = 390.0 Da. Middle panel: A FITC-subtilisin peptide (137–145, 1221.2 Da) was identified at 
RT = 23.88 min. Bottom panel: Subsequent MS/MS fragmentation on the same peptide molecule confirmed its sequence.
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Table 1: Binding of FITC-Subtilisin to Immuno-adsorbantsa
RFU Anti-Subtilisin Anti-FITC Control Antibody
Initial RFU 244 244 244
Bound 113 80 6
Eluted 14.6 5.6 1.4
a12 µg of FITC-subtilisin (20.3 RFU/ug protein) were mixed with 0.1 ml of each immunoadsorbent in triplicate, in a total volume of 1 ml of 
Dulbecco's PBS containing 0.05% BSA and 2 mM PMSF, overnight at 4°C for 18 hr.
Table 2: In Vitro hydrolysis of FITC-Subtilisin to < 10 K by Preiss Cell Extractsa
Cell Fraction pH 5.2 pH 5.2 pH 7.7 pH 7.7
Cell Extract + - + -
Initial RFU 100 100 100 100
< 10 K Fraction 44 0.46 27 19
aPreiss cell extracts (50 µl) were adjusted to pH 5.2 with 0.1 M sodium acetate or to pH 7.7 with 0.1 M sodium bicarbonate in a total volume of 1 
ml and incubated with 15 µg of PMSF inactivated FITC-subtilisin (22 RFU/µg protein) at 37°C for 4 hr. The contents of each tube were centrifuged 
on a Centriprep YM-10 concentrator and the percentage of fluorescent activity recovered in the low molecular weight fraction calculated.
Table 3: Tracking FITC-Subtilisin in an antigen uptake experiment with acid extractiona
Cell Fraction RFUs Protein (µg) % Recovered
Conjugate added 140,000 15555 100%
Washed cells 750 83 0.53
Cell extract 261 29 0.18
< 10 K fraction 26 2.9 0.018
a5 × 108 8.1.6 cells were resuspended in 300 ml of complete media, mixed with 15.5 mg of fluorescein-subtilisin and incubated for at 37°C for 24 hr 
in a roller bottle.
Table 4: Summary of Treatments to Increase Exogenous Uptake of FITC-Subtilisin
Treatment Uptake and Processing
1. Active Subtilisin Cell Lysis
2. TCA-precipitated FITC-subtilisin Uptake, no increase in processing
3. Autolysed FITC-subtilisin Uptake, no increase in processing
4. FITC-subtilisin antibody conjugate Uptake, no increase in processing
5. FITC-subtilisin crosslinked with glutaraldehyde Uptake, no increase in processing
6. Carriers (BioPorter, Chariot, TAT peptide) + FITC-subtilisin Uptake, no increase in processing
7. Liposomes + FITC-subtilisin Uptake, no increase in processing
8. Alpha-2-macroglobulin + FITC-subtilisin No increase
9. IFN gamma + FITC-subtilisin 10–25% increase in processing
10. Pulse 2 hr, 12 hr, 24 hr, 36 hr, 48 hr 24 hr best
11. Antigen dose 100–900 µg/mL 100–200 µg/mL bestBMC Immunology 2004, 5:12 http://www.biomedcentral.com/1471-2172/5/12
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tilisin and HLA-DR was extracted from the cell lysates.
These cells are more proficient at antigen uptake than B
cell lines though less amenable to large-scale cultures. DR-
bound peptides were eluted and analyzed on the Q-TOF
and a subtilisin peptide was identified (Table 6) in a sin-
gle experiment. This peptide corresponded to a region of
subtilisin, 70–84 that had been identified as an epitope in
another study (unpublished data).
Discussion
The use of fluorescent conjugates to investigate immuno-
logical processes has a long history. This study exemplifies
their use in tracking antigen to identify optimal condi-
tions for antigen uptake and processing.
Subtilisin is one of the most extensively studied of all bac-
terial proteins, due to its commercial importance [20,21].
Our laboratory is interested in its potential role as an anti-
gen [13]. In order to identify naturally processed peptides
from subtilisin, we devised a simple way to label, stabi-
lize, measure, and track the protein in cell studies. We
demonstrate the preparation and characterization of
FITC-subtilisin conjugates, and analysis of antigen taken
up and processed by human cell lines.
We have shown that subtilisin can be labelled with FITC
with generally two or fewer moles of FITC per mole of pro-
tein. These conjugates retain antigenicity and up to 30%
of their enzymatic activity on small substrates. These
conjugates can be degraded by cellular extracts of mam-
malian cells at pH 5.3 showing the FITC label does not
prevent hydrolysis. We show that the fluorescein residues
on FITC-subtilisin are present on the N terminus and two
other lysine residues. Though the final processed peptides
may contain these fluorescein residues, they are present in
minute amounts in the low molecular weight fractions,
precluding RFU detection within the sensitivity of our cur-
rent detection systems.
Mass spectrometry analysis of the low molecular weight
fraction showed detectable and identifiable subtilisin
peptides when the specific RFU/µl of sample was 0.5 or
more. Thus, using the 10 K fraction, if 50 RFU are isolated
after peptide elution, assuming an average mw of 1500
daltons, this signa1 represents about 55 ng of peptides.
The 55 ng peptides when prepared for mass spectrometry
analysis would be in the picomole to subpicomole range,
which is consistent with current mass spectrometry
detection limits and with the calibrated sensitivity of our
LC-MS system at 0.5–1.0 picomoles of peptide spiked into
cell extracts without antigen. Our detection limits are also
comparable to reports in the literature where self-peptides
presented by class II MHC molecules induced by a
measles vaccine virus infection were present at 0.5 pmol
and identified [22].
Our results show that although cell associated RFUs fol-
lowing extensive washes could be indicative of impressive
uptake responses; these did not translate to processing of
antigen into low molecule weight peptides in the cell
Table 5: Tracking FITC-Subtilisin in a large scale antigen uptake experiment with immuno-affinity purificationa
Fraction RFUs Protein (µg) % Recovered
Pulsed Cells 133800 223000 100%
Washed Cells 1358 22630 1
Cell lysate 558 930 0.4
Immunoaffinity column flow-through 343 571 0.20
< 10 K flow-through fraction 79.2 132 0.06
DR-eluted peptides 31 51 0.02
a8.5 × 109 8.1.6 cells were mixed with 223 mg of conjugate (0.6 RFU/ug) in 1600 ml of complete media and incubated at 37°C for 22 hr.
Table 6: Subtilisin Peptides Identified from Subtilisin Antigen Uptake in Human Cells
Cells HLA Peptide Source Subtilisin peptide Peptide sequence Theory (Da) Found (Da) Ion match
8.1.6 DR3 Cell extract 114–126 AIANNMDVINMSL 1405.7 1406.1 10/24
Preiss DR4 Cell extract 108–122 INGIEWAIANNMDVI 1672.8 1671.6 9/28
8.1.6 DR3 Cell extract 43–53 KVAGGASMVPS 1003.5 1004.3 10/20
KG-1 DR11, DR14 DR-bound 70–84 * GTVAALNNSIGVLGV 1384.6 1384.78 12/28
* Identified by Q-TOF analysis. The others were identified by LC-MS analysis.BMC Immunology 2004, 5:12 http://www.biomedcentral.com/1471-2172/5/12
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extracts or into peptides bound to MHC molecules. We
believe the high RFUs associated with cells may be non-
specific adherence of the antigen to the cell membranes.
The B-LCL cells endocytosed very minute amounts of anti-
gen (less than 1% of incubated antigen), of which only
10–20% were low molecular weight peptides of less than
10,000 daltons. In conclusion, despite testing several dif-
ferent conditions, none increased antigen uptake signifi-
cantly in the B-LCL cells, consistent with the low efficiency
of non-receptor mediated antigen uptake by B cells [9,23].
Our peptide analysis results from multiple experiments
shows three distinctive regions of the subtilisin molecule
that are detected in the cellular extracts by mass spectrom-
etry. The one DR-bound peptide detected is from a
different region of the molecule and corresponds to a pre-
viously identified subtilisin epitope (unpublished data).
This DR-bound peptide was analyzed on the Q-TOF,
which is more sensitive than the LC-MS system. The pep-
tides detected in the cellular extracts by LC-MS could be
peptides that are processing intermediates of peptides to
be bound and presented on class I or class II molecules or
simply regions of the protein more stable in the presence
of cellular degrading enzymes. Our data do not distin-
guish between these possibilities.
Conclusions
In conclusion, we have demonstrated that FITC conjuga-
tion can be used successfully to track antigen uptake and
processing and detect processed peptides in the cellular
extracts and DR-bound peptides in human cells. This
method is simple, efficient, and relatively inexpensive.
Thus it would be useful to study the uptake and process-
ing of several other antigens. Improved mass spectrometry
methods to detect the presence of MHC bound naturally
processed peptides would further enhance the utility of
the described method. Our future studies will focus on
studying uptake and processing of other FITC labelled
antigens and improving mass spectrometry methods to
detect the presence of other MHC bound naturally proc-
essed peptides.
Methods
Enzyme
Subtilisin was a single amino acid mutant (BPN' Y217L)
prepared from Bacillus amyloliquefaciens (Swissprot acces-
sion number P00782) and purified by crystallization. It
was formulated in 50% glycerol at 55 mg/ml and stored at
-17°C, where it was stable. Subtilisin activity was meas-
ured in a kinetic assay with the synthetic substrate
sucAAPF-pNA as previously described [20].
Preparation of FITC-subtilisin conjugates
Two milliliters of enzyme were desalted over a Sephadex
G-25 column (PD-10 Sulpeco, Bellefonte, FA) equili-
brated in 100 mM sodium carbonate, pH 9 at 4°C. Phe-
nylmethyl sulfonyl fluoride (PMSF) (Sigma Chemical
Co., St. Louis, MO) dissolved at 100 mM in absolute eth-
anol was added to 2 mM FITC mixed isomer (Sigma
Chemical Company, St. Louis, MO) dissolved at 2 mg/ml
in 100 mM sodium carbonate buffer. In an ice bath, 0.5
ml of FITC solution was added to 2 ml of enzyme contain-
ing 5 to 50 mg/ml and the reaction allowed to proceed in
the dark for 90 minutes and then an additional 0.25 ml of
FITC solution was added for 30 min. FITC conjugated sub-
tilisin (FITC-subtilisin) was isolated by Sephadex G-25
chromatography equilibrated in Dulbecco's PBS, pH 7.1
at 4°C. The collected void volume containing FITC-sub-
tilisin was brought to 2 mM PMSF, covered in aluminum
foil, and stored in aliquots at -17°C.
Characterization of FITC-subtilisin conjugates
Protein concentration was measured using the BCA Pro-
tein Assay (Pierce, Rockford, IL) adapted to microtiter
plates using a bovine serum albumin standard. Relative
fluorescent units (RFU)/µg protein were determined on
an fmax Fluorescence Microplate Reader (Molecular
Devices Corp. Sunnyvale, CA), with 485 nm excitation
and a 535 nm emission filters. Experimental samples were
assayed in triplicate by dilution in Dulbecco's PBS to RFU
values of 50 or less. Blank values were corrected if they
were 1 RFU or more. Comparisons between experiments
used conjugates with comparable RFU/protein activities,
generally between 20 and 22 RFU/µg protein. Reproduci-
ble differences of 25% or more were considered
significant.
Cells
EBV-transformed B lymphoblastoid cell lines 8.1.6, and
Preiss, were a kind gift from Dr. Elizabeth D. Mellins,
Stanford Univ., CA [24]. KG-1 cells were obtained from
ATCC [21]. Both cell types were grown by culture in RPMI
1640 1X (MOD) media with 25 mM Hepes buffer (Medi-
atech, Herndon, VA), Heat-inactivated fetal bovine serum
(HyClone, Logan, Utah) was added to 10 % along with 55
µM 2-ME, 100 µg/ml streptomycin, 100 U/ml of penicil-
lin, and 0.29 mg/ml glutamine (Life Technologies, Grand
Island, NY). Large quantities of cells were grown in 2 L
roller bottle culture flasks (Corning Inc., Corning, NY).
Pulsing and harvesting cells
Cells were cultured to 1–1.2 × 106/ml and resuspended in
400 ml of complete medium to a concentration between
0.5–1 × 107 per ml and 150–250 µg/mL PMSF inactivated
FITC-subtilisin. Cells were cultured at 37°C for 2 hr and
then diluted 1:2 in complete medium. After 20 hrs cells
were washed extensively in Dulbecco's PBS.BMC Immunology 2004, 5:12 http://www.biomedcentral.com/1471-2172/5/12
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Acid lysis of cells
Washed cell pellets were lysed by adding 0.2 M HCL to a
final concentration of 1 × 108 cells/ ml and shaken vigor-
ously for 45 min at 4°C. Cells were centrifuged at 15,000
g for 30 min in a Sorvall RC-5B Centrifuge (Sorvall Cen-
trifuges, Newtown, CT) and the supernatant was concen-
trated in an Amicon Centriprep YM-10 filter device
(Millipore Inc., Billerica, MA) at 3000 g. The fraction less
than 10 K was collected and frozen at -17°C, or lyophi-
lized and stored at -17°C. To remove salt and reduce
detergent from low molecular weight fractions, acid cell
extracts and detergent lysates were purified on 100 mg, 3
ml Bond Elut-C18 columns (Varian, Harbor City, CA).
The FITC associated fractions were eluted in 1 ml of 50%
acetonitrile. Eluted peptides were lyophilized and stored
at -17°C until analyzed.
DR purification
For affinity purification of HLA-DR molecules, washed
cells were resuspended in lysis buffer (0.1 % Nonidet P-
40, 50 mM Tris-HCL pH 8.5, 0.15 mM NaCl) at 1 × 108
cells /ml following the procedure of Gorga et al. [25].
Briefly, cells were lysed using15 lbs nitrogen pressure at
4°C in a 35 ml Parr implosion device (Parr Inst. Co.,
Moline, IL), and homogenized 30X in a 100 ml Dounce
Homogenizer (Kontes Glass Co., Vineland, NJ). Extracts
were cleared of debris and nuclei by centrifugation at
10,000 × g for 1 hr at 4°C and the supernatant fluid con-
taining solubilized HLA DR molecules was purified by
affinity chromatography as described [9]. The eluate was
separated into a low molecular weight (10 K) fraction as
described above and frozen at -17°C.
Preparation of immunoadsorbents
Subtilisin and purified polyclonal antibody to subtilisin
were coupled to cyanogen bromide-activated Sepharose
(Sigma Chemical Co., St. Louis, MO) as described [26].
Mouse monoclonal antibody against FITC was purchased
from Sigma Chemical Co. and immobilized similarly.
Peptide synthesis, HPLC, mass spectrometry, MS data 
analysis
Subtilisin peptides 70–84 and 114–126 were synthesized
(Applied Biosystems, 4331 Peptide Synthesizer, Foster
City, CA) in-house and purified to 90%. All MS and MS/
MS data were acquired using the Agilent 1100 HPLC sys-
tem (Agilent Technologies, Palo Alto, CA) coupled to the
LCQ Classic Ion Trap Mass Spectrometer (ThermoFinni-
gan, San Jose, CA) or the CapLC system with the Q-TOF
Ultima API MS (Micromass, Milford, MA). The HPLC gra-
dient was programmed from 0 to 70% B over 70 minutes.
Solvent A: 0.1% formic acid (FA) in water and solvent B:
0.1% FA in acetonitrile. Data processing was performed
using TurboSequest and Xcalibur software (ThermoFinni-
gan) or the Masslynx program (Micromass).
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